Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Nicolet Advisory Services LLC

Nicolet Advisory Services LLC cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,480 shares of the biopharmaceutical company’s stock after selling 214 shares during the period. Nicolet Advisory Services LLC’s holdings in Gilead Sciences were worth $293,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in GILD. Waverly Advisors LLC lifted its stake in Gilead Sciences by 7.8% in the first quarter. Waverly Advisors LLC now owns 26,455 shares of the biopharmaceutical company’s stock valued at $1,938,000 after buying an additional 1,910 shares during the last quarter. Bayesian Capital Management LP purchased a new position in shares of Gilead Sciences in the first quarter valued at $1,187,000. Kennedy Capital Management LLC acquired a new stake in shares of Gilead Sciences in the first quarter valued at approximately $2,946,000. Jacobs Levy Equity Management Inc. grew its holdings in Gilead Sciences by 306.2% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 517,770 shares of the biopharmaceutical company’s stock valued at $37,927,000 after buying an additional 390,301 shares during the last quarter. Finally, Elkhorn Partners Limited Partnership increased its position in Gilead Sciences by 171.4% during the 1st quarter. Elkhorn Partners Limited Partnership now owns 950 shares of the biopharmaceutical company’s stock worth $70,000 after purchasing an additional 600 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the transaction, the insider now directly owns 100,189 shares in the company, valued at $8,398,843.87. The trade was a 1.96 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the transaction, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. The trade was a 27.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 56,947 shares of company stock worth $4,968,674 over the last three months. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on GILD. Leerink Partners upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and upped their target price for the company from $74.00 to $96.00 in a research note on Monday, October 21st. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Thursday, November 7th. BMO Capital Markets lifted their price target on shares of Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Piper Sandler increased their target price on Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Finally, Daiwa America raised Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. Twelve analysts have rated the stock with a hold rating, eleven have issued a buy rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $95.41.

Gilead Sciences Stock Up 0.5 %

GILD stock opened at $90.19 on Monday. The firm has a 50 day simple moving average of $87.43 and a 200-day simple moving average of $76.95. The company has a market capitalization of $112.40 billion, a P/E ratio of 1,002.11, a PEG ratio of 2.78 and a beta of 0.17. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same period last year, the business posted $2.29 earnings per share. On average, equities research analysts predict that Gilead Sciences, Inc. will post 4.38 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be issued a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 3.42%. The ex-dividend date of this dividend is Friday, December 13th. Gilead Sciences’s payout ratio is currently 3,422.22%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.